News | March 21, 2022
Lonza signs manufacturing agreement with Oasmia Pharmaceutical
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Prashant comes with over 17 years of experience in the health, health insurance and other allied healthcare sectors
The investment will accelerate the overall Sarclisa development program
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Deploying solutions like Uniphore’s U-Self Serve and U-Assist with SpinSci’s Patient Engage and Patient Assist is an important step forward in creating frictionless patient experiences
He has over 25 years of rich experience in marketing and business in various sectors
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
In numerous neurological and rare disorders, where clinical characteristics can be confusing, NGS-based approaches have demonstrated considerable increases in disease detection rates over other approaches
Subscribe To Our Newsletter & Stay Updated
